Studies in men and women show efficacy against lesions related to HPV
-6, 11, 16 &18 to be >90%.
The vaccine contains only strains which have been implicated in formation of secondary cancers. In addition to reducing the risk of infection and cancers due to these strains it also reduces the chance of potentially infected people from transmitted infection to others. It is highly effective.